Viritis

Viritis Overview

Viritis is a biotech company pioneering a next-generation antisense-based platform for rapid development of antiviral drugs. Our novel technology targets all strains of a given virus, offering a scalable and precise solution for current and emerging viral threats. Our platform combines AI-driven algorithms with patented molecule design to bind specifically to viral RNA. Once attached, it activates the cell’s innate defense mechanisms, degrading the virus from within— without harming the host. After completing its function, the molecule naturally disintegrates within hours, leaving no harmful residues. In POC studies, our platform demonstrated 97.1% cellular protection against the target virus. Its innovative structure also makes it highly stable, can be lyophilize, and easy to store and transport—ideal for global deployment.

Cumulative Funding Raised Over Time ($)

Latest News

Sep 4, 2025 · www.nature.com

growth-positive

Advancing antivirals - Nature Biotechnology AI can also be used to design antiviral drugs. A company based in Israel, Viritis, is using AI to design antiviral antisense therapy drugs that can enter a cell, bind a virus-specific RNA sequence and target it for degradation.

The article discusses the declining public trust in vaccines in the United States and the shift in funding towards broader vaccine platforms and antiviral research. It highlights the potential of antivirals as a complementary approach to vaccines, especially in the face of viral mutations. Companies like Viritis are using AI to design antiviral drugs, while Red Queen Therapeutics is developing peptides targeting viral fusion. The article notes the late-2024 investment by Gilead in Assembly Biosciences to advance antiviral therapies. Despite the promising research, antivirals are not a replacement for vaccines and require more funding and development.

InvestmentProduct Stage

May 8, 2025 · www.haaretz.com

growth-positive

THE ISRAELI COMPANY REVOLUTIONIZING ANTIVIRAL TREATMENT

Viritis, a biotech company founded during the COVID-19 pandemic, is developing a novel AI-driven antiviral drug that targets viruses inside infected cells. The company has made significant scientific breakthroughs, including a patented antisense therapy that is both stable and selective for viral material. Viritis has secured funding from the Israel Innovation Authority and is part of the NVIDIA Inception Program, which aids in enhancing its AI algorithms. The company is preparing to enter clinical trials and aims to secure FDA approval. Viritiss technology promises to shorten development timelines for antivirals and has potential applications beyond viruses, including cancer treatment.

InvestmentProduct StagePartners

Funding

Team Members

8

Employees: 1-10

Web & Social Links

Locations

Petah Tikva, Israel

Photos & Videos

3 item(s)

Viritis Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info